Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

近年来，国内外大量研究均已表明，HBV在肝内形成的共价闭合环状DNA（HBV cccDNA）库的持续存在与HBV慢性持续性感染以及慢性乙型肝炎（CHB）难以治愈 ...

Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.

Discover a clinical trial that was conducted to evaluate the efficacy and safety of autologous HBV vaccine-pulsed dendritic cells and their induced T cells.

Twenty-seven patients with Chronic Hepatitis B Virus infection (CHB) have now been dosed with VRON-0200 as a single (Prime), or Prime and Boost, intramuscular (i.m.) injection ...